1 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 1 Overcoming treatment-resistance in chronic depression: A pilot study on outcome and feasibility of the Cognitive Behavioral Analysis System of Psychotherapy as an inpatient treatment program Eva-Lotta Brakemeier, Martina Radtke, Vera Engel, Johannes Zimmermann, Brunna Tuschen-Caffier, Martin Hautzinger, Elisabeth Schramm, Mathias Berger, Claus Normann Online Supplementary Material A A1 Detailed description and explanation of the CBASP inpatient concept The CBASP inpatient treatment based on the CBASP concept by McCullough [2,A1] was established in 2008 and has been manualized . The CBASP inpatient program includes the following CBASP specific therapy components: individual therapy (two sessions of 50 minutes/week), group psychotherapy (two sessions of 90 minutes/week), physiotherapy with Kiesler Circle Training (one session of 60 minutes/week), occupational group (two sessions of 90 minutes/week), nurse-patient encounters (at least one session of 30 minutes/week), and social worker contact (at least one session of 30 minutes/week). In the CBASP introduction phase, significant other history and transference hypotheses are compiled in four individual sessions and discussed in the CBASP team meeting. The patient s significant others denote the significant persons who have left their positive or negative stamps on the individual shaping how he or she behaves and determining what he or she has come to expect in interpersonal relationships. The transference hypothesis, developed in collaboration with
2 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 2 the patient, is a predictive hypothesis about what the patient is likely to expect from the therapist and how the patient is likely to behave interpersonally in treatment. As a modification to the outpatient treatment, transference hypotheses are not only formulated for the individual therapist but also for the treatment ward team and for the patient group. In the CBASP main phase, the patient starts with the three CBASP group therapies, in addition to ongoing individual psychotherapy sessions, nurse encounters, and social worker contacts. This phase focuses on the intensified use of the Kiesler circle and on conducting situational analyses with subsequent role-playing events to modify inappropriate behavior. By operating with the Kiesler circle the patients get a deeper understanding of their stimulus character and its impact on others. The situational analysis is the major strategy of CBASP which aims to teach patients skills to focus on attainable desired outcomes and to use adequate interpretations and behavior to reach them. The situational analysis helps patients to address their problematical situations in behavioral ways. It is also designed to demonstrate patients the link between their own behavior and the interpersonal consequences, since the consequences they report are, for the most part, self-produced. Moreover, CBASP uses the relationship with the therapist and other team members as a tool to help patients to become more aware of their impact on others and to distinguish between adaptive and maladaptive interpersonal relationships. Thus, interpersonal hotspot situations were utilized to offer interpersonal healing experiences by using the disciplined personal involvement with interpersonal discrimination exercises. The aims of these strategies are to modify pathological behavior, to connect patients with their interpersonal environment, and to break the cycle of preoperational functioning [2,11,A1]. In the final phase, i.e., the last two weeks of the inpatient treatment, arrangements are made for hospital discharge and for the continuation of the therapy in the outpatient setting. If patients continue applying the
3 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 3 learned CBASP strategies and want another opportunity for treatment in the inpatient CBASP concept, they can attend a CBASP refresher course lasting four weeks at least six months after their first discharge. In addition, in some cities, CBASP patient support groups have been established to avoid relapse after discharge . The entire CBASP treatment team involved in this study was trained in CBASP by ELB and ES (both certified CBASP trainer). The team consisted of two physicians, two clinical psychologists, nine nurses, and four additional therapists (two art therapists, one physiotherapist, and one social worker). All individual CBASP therapists (five clinical psychologists and three psychiatric residents during the study period) had completed or were in an advanced stage of their psychotherapy training. For the team, the following CBASP components have been established: team meeting (90 minutes/week), individual supervision for the therapists (60 minutes/week), team supervision (120 minutes/month), and ongoing trainings for the staff (240 minutes/every second month). A2 Additional information concerning feasibility and acceptance To summarize the acceptance questionnaires, the following percentage of completer patients (N=65) rated the CBASP components as helpful or very helpful : 92.9% physiotherapy with Kiesler Circle Training, 91.2% individual therapy, 87.7% group psychotherapy, 86.2% nurse-patient encounters, 73.9% social worker contact, and 64.7% occupational group. In total, 90.4% judged the overall concept as helpful or very helpful. Concerning CBASP strategies, the therapeutic relationship and the resulting interpersonal experiences were judged as most helpful regarding the individual therapy. The use of the Kiesler circle and the situational analyses were perceived as the most helpful group strategies.
4 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 4 The acceptance of and satisfaction with the CBASP concept by the treatment team was high [A2], and there were no persistent difficulties integrating the concept into the clinical routine. A3 Additional information concerning the depressive symptomatology and outcome-rates Figure A1 illustrates the treatment response for each patient of the completer sample, demonstrating that no patient deteriorated. Figure A1. Treatment results of the inpatient CBASP program in the completer sample (N=65). Note. Scatter plot of the individual HAMD 24 (Hamilton Rating Scale for Depression, 24 items, scale 0-75 ) scores before and after treatment. All cases below the black diagonal line improved. The unfilled cases are the non-responders (note: two cases 31/23); the filled cases above the red line are the responders; the filled cases below the red line responded and also remitted. Non-responder = not fulfilling criteria for response; responder = fulfilling criterion for response: decrease in symptom severity of at least 50% on the HAMD 24 from pre to post treatment; remitter = fulfilling criteria for
5 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 5 remission: a score of 10 or less on the HAMD 24 scale in post treatment. Due to these criteria, all remitters were also responders. The Figure 1 in the manuscript presents the estimated trajectories of change in MADRS , IDS-SR , HAMD 24 , and BDI-II  in the ITT-sample based on linear mixed-effect models. MADRS and IDS-SR scores steadily decreased during treatment. At discharge, MADRS scores were reduced by points (SE = 1.18, p <.001, d = 1.89) and IDS- SR scores were reduced by points (SE = 1.59, p <.001, d = 1.02). Moreover, HAMD 24 scores decreased by points by the time of discharge (SE = 1.01, p <.001, d = 2.52). This decrease was also relatively stable during follow-up, with points at the six-month follow-up (SE = 1.18, p <.001, d = 2.08) and with points at the 12-month follow-up (SE = 1.18, p <.001, d = 1.91). Similarly, BDI-II scores decreased by 14.6 points by the time of discharge (SE = 1.78, p <.001, d = 1.15). Again, this decrease was relatively stable during followup with points at the six-month follow-up (SE = 2.12, p <.001, d = 0.88) and with 10.3 points at the 12-month follow-up (SE = 2.13, p <.001, d = 0.81). The Table A1 summarized the observed HAMD 24 and BDI-II values at pre, post, six-month, and 12-month follow-up measurement points. Table A1. Descriptive statistics of the HAMD 24 and BDI-II values at pre, post, 6-months, and 12-months follow-up measurement HAMD 24 1 BDI-II 2 n M SD N 3 M SD Pre Post months months Note. 1 Hamilton Rating Scale for Depression, 24 items, scale 0-75 ; 2 Beck Depression Scale, version II, scale 0-63 ; 3 Since BDI is a self-rating instrument and not all severely depressed patients could be motivated, the number of patients with completed data is lower in the BDI than in the HAMD being an observer rated interview.
6 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 6 A4 Additional information concerning the interpersonal impact messages In this study, the Impact Message Inventory [IMI-R; 20] based on the interpersonal circle model by Kiesler [A3] was used to assess the impact message of a patient rated by the therapist. Impact messages are defined as experiences of subtle interpersonal pressures in the communication with another person about what he or she wants the other person to do or not to do [A4]. The IMI-R is developed within the interpersonal tradition [A5]. It is assumed that all interpersonal behaviour patterns can be accounted for by a combination of two central descriptive dimensions: agency and communion. Both span a two-dimensional space referred to as the interpersonal circumplex. In the IMI-R, the interpersonal space is subdivided into eight octants representing combinations of agency and communion, such as hostile-submissive or friendly-dominant [A6,A7]. Figure A2 presents the estimated changes in IMI-R ratings in the ITTsample based on linear mixed-effect models. Patients were perceived by their individual therapists as significantly more dominant (B = 0.73, SE = 0.07, p <.001, d = 1.69), friendly-dominant (B = 0.98, SE = 0.08, p <.001, d = 1.84), and friendly (B = 0.85, SE = 0.09, p <.001, d = 1.69), and as significantly less friendly-submissive (B = -0.49, SE = 0.08, p <.001, d = -0.96), submissive (B = -0.98, SE = 0.10, p <.001, d = -1.41), hostile-submissive (B = -0.91, SE = 0.10, p <.001, d = -1.47), hostile (B = -0.59, SE = 0.09, p <.001, d = -1.34), and hostile-dominant (B = , SE = 0.08, p =.013, d = -0.42). In short, patients improved considerably in terms of dominance and affiliation. The significant modification of patients stimulus character (measured by the IMI-R rated by the therapist) underlines McCullough s view that CBASP is effective in improving interpersonal functioning [2,A1]. Patients improved considerably in terms of dominance and affiliation, which might be supported by the integration of the Kiesler circle into the group
7 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 7 therapies. In line, a study with data of the Keller trial  found that the CD patients were less hostile and more friendly after therapy [A6]. Of note, the IMI-R was used as a therapeutic instrument in the individual sessions. Thus, the therapists were neither blinded nor objective raters, so there are limitations to the validity of these interpretations. In a future study, the IMI-R should be rated by blinded raters or even by significant others, as in one published trial [A7]. Figure A2. Change in patient stimulus character before and after inpatient treatment Note. IMI-R (Impact Message Inventory Revised)  mean scores of the eight stimulus characteristics of the Kiesler Circle as judged by the individual therapists for their patients before and after treatment.
8 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 8 References Supplementary Material A A1. McCullough JP: Treating chronic depression with disciplined personal involvement, Cognitive Behavioral Analysis System of Psychotherapy. New York, Springer, A2. Brakemeier EL, Engel V, Radtke M, Gumz A, Berger M, Normann C: How did the implementation of a disorder-tailored inpatient CBASP concept for chronically depressed patients influence acceptance, satisfaction, and burnout levels of the treatment team over two years? (in preparation). A3. Kiesler DJ: The 1982 Interpersonal Circle: A taxonomy for complementarity in human transactions. Psychol Rev 1983;90: A4. Pincus AL, Lukowitsky MR, Wright AGC: The interpersonal nexus of personality and psychopathology. In: T Millon, R Kreuger, E Simonsen (Eds.), Contemporary directions in psychopathology: Scientific foundations for DSM-V and ICD-11 (pp ). New York, Guilford Press, A5. Hafkenscheid A: Assessing objective countertransference with a computer-delivered Impact Message Inventory (IMI-C). Clin Psychol Psychother 2012;19(1): A6. Constantino MJ, Manber R, Degeorge J, McBridge C, Ravitz P, Zuroff DC, Klein DN, Markowitz JC, Rothbaum BO, Thase ME, Arnow BA: Interpersonal styles of chronically depressed outpatients: Profiles and therapeutic changes. Psychotherapy 2008;45(4): A7. Grosse Holtforth M, Altenstein D, Ansell E, Schneider C, Caspar F: Impact messages of depressed outpatients as perceived by their significant others: Profiles, therapeutic change, and relationship to outcome. J Clin Psychol 2011;67(0):1 15.
9 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 1 Overcoming treatment-resistance in chronic depression: A pilot study on outcome and feasibility of the Cognitive Behavioral Analysis System of Psychotherapy as an inpatient treatment program Eva-Lotta Brakemeier, Martina Radtke, Vera Engel, Johannes Zimmermann, Brunna Tuschen-Caffier, Martin Hautzinger, Elisabeth Schramm, Mathias Berger, Claus Normann Online Supplementary Material B Table B1. Add-on Medication of the Intention-to-Treat Sample for each Response Group at Baseline. Add-on Medication Remitter (n = 28) Responder (n = 25) Non-Responder (n = 12) Dropout (n = 5) All (N = 70) p Antidepressants Percent receiving no antidepressant Percent receiving one antidepressant Percent receiving two or more antidepressants
11 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 3 Add-on Medication Remitter (n = 28) Responder (n = 25) Non-Responder (n = 12) Dropout (n = 5) All (N = 70) p Antipsychotics antipsychotic Specific received antipsychotics Atypical antipsychotic Not atypical antipsychotic (low-potency antipsychotic) Mood Stabilizer mood stabilizer Specific received mood stabilizer Lithium Anticonvulsant (e.g., valproic acid, topiramate, gabapentin, lamotrigine) Anxiolytic and Hypnotic Drugs anxiolytic and hypnotic drug Specific received anxiolytic and hypnotic drugs Benzodiazepine
12 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 4 Add-on Medication Remitter (n = 28) Responder (n = 25) Non-Responder (n = 12) Dropout (n = 5) All (N = 70) p GABAergic Substances (e.g., zolpidem, zopiclone) Stimulants stimulant Specific received stimulant Methylphenidate Modafinil Note. All values are percentages. p values are results of chi-square statistics.
13 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 5 Table B2. Add-on Medication of the Intention-to-Treat Sample for each Response Group at Discharge. Add-on Medication Remitter (n = 28) Responder (n = 25) Non-Responder (n = 12) Dropout (n = 5) All (N = 70) p Antidepressants Percent receiving no antidepressant Percent receiving one antidepressant Percent receiving two or more antidepressants Specific received antidepressants Selective serotonin reuptake inhibitor (e.g., citalopram, sertraline) 5HT/noradrenaline reuptake inhibitor (e.g., venlafaxine, duloxetine) Noradrenaline/dopamine reuptake inhibitor (e.g., bupropion) Tricyclic antidepressants (e.g., trimipramine) Tetracyclical antidepressants (e.g., mirtazapine) *
14 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 6 Add-on Medication Remitter (n = 28) Responder (n = 25) Non-Responder (n = 12) Dropout (n = 5) All (N = 70) p Other antidepressants Agomelatine Reboxetine * Trazodone Antipsychotics antipsychotic Specific received antipsychotics Atypical antipsychotic Not atypical antipsychotic (low-potency antipsychotic) Mood Stabilizer mood stabilizer Specific received mood stabilizer Lithium Anticonvulsant (e.g., valproic acid, topiramate, gabapentin, lamotrigine)
15 Brakemeier et al.: An inpatient CBASP program. Psychoth Psychosom. 7 Add-on Medication Remitter (n = 28) Responder (n = 25) Non-Responder (n = 12) Dropout (n = 5) All (N = 70) p Anxiolytic and Hypnotic Drugs anxiolytic and hypnotic drug Specific received anxiolytic and hypnotic drugs <.001* Benzodiazepine <.001* GABAergic Substances (e.g., zolpidem, zopiclone) Stimulants stimulant Specific received stimulant * Methylphenidate Modafinil Note. All values are percentages. p values are results of chi-square statistics.
Step 4: Complex and severe depression in adults A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive
What are the best treatments? Description of Condition Depression is a common medical condition with a lifetime prevalence in the United States of 15% among adults. Symptoms include feelings of sadness,
I. Specific Aims/Objectives STAR*D has several main objectives and is powered to assess the effectiveness of a sequence of treatments at various levels of treatment. Most of these objectives entail evaluating
Update on guidelines on biological treatment of depressive disorder Dr. Henry CHEUNG Psychiatrist in private practice 2013 update International Task Force of World Federation of Societies of Biological
Guidance for safe transfer of prescribing Background information The majority of medicines prescribed to treat mental health illnesses are covered by NICE guidance. Where prescribing follows NICE recommendations
Management of moderate to severe ere (including psychotic) depression in children and young people tiers 2 4 bring together all NICE guidance, quality standards and other NICE information on a specific
Mohammad Amjad ullah Khan, M.D. Child, Adolescent and Adult Psychiatry Texas A & M University Scott & White Healthcare System Temple and Killeen Sadness of mood for most of the day, nearly every day, and/or
Antidepressant treatment in adults A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive and
Best Practices Treatment Guideline for Major Depression Special Report on New Depression Treatment Technology Based on 2010 APA Practice Guidelines Best Practices Guideline for the Treatment of Patients
Using antidepressants in children and young people bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,
Health Care Service System in Thailand for Patients with Alcohol Use Disorder Health Care Service System In Thailand Screening for alcohol use disorder and withdrawal syndrome AUDIT MAST CAGE CIWA or AWS
Step 2: Recognised depression in adults persistent subthreshold depressive symptoms or mild to moderate depression A NICE pathway brings together all NICE guidance, quality standards and materials to support
Formulary for mental health medications The Medicines Management Committee has approved this list of formulary medicines with links to national and local prescribing guidelines. If a medicine for a mental
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
Bipolar Disorder: Advances in Psychotherapy Questions from chapter 1 1) Which is characterized by one or more major depressive episodes with at least one hypomanic episode in which the patient s functioning
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that
Case Number: CM13-0018009 Date Assigned: 10/11/2013 Date of Injury: 06/11/2004 Decision Date: 01/13/2014 UR Denial Date: 08/16/2013 Priority: Standard Application Received: 08/29/2013 HOW THE IMR FINAL
MANAGING PATIENTS WITH CHRONIC MENTAL HEALTH PROBLEMS IN PRIMARY CARE Dr Ilyas Mirza Psychiatric Consultant Barnet Enfield & Haringey Mental Health Trust CHRONIC MENTAL HEALTH Anxiety disorders PROBLEMS
Medications for bipolar disorder Findings from Australian National Survey of Mental Health and Wellbeing (Mitchell et al, 2004) In 12 months, only one-third saw a mental health professional 40% received
Isabella Pacchiarotti, M.D., Ph.D. Breastfeeding is recommended by the American College of Obstetricians and Gynecologists, the American Academy of Pediatrics, and the WHO The latter recommends exclusive
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
Topic NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Depression in adults: treatment and management This guideline will update the NICE guideline on depression in adults (CG90) as set
Member Rights & Responsibilities Member Rights and Responsibilities Blue KC has updated our Member Rights & Responsibilities to be consistent across all of our HMO and PPO products. Blue KC members have:
Treatment: Healing Actions, Healing Words 15 : Insight-Oriented Therapy Psychoanalysis (p.687) First use of a talking cure Developed by Sigmund Freud Identify unconscious motivations Free association Dream
DEPARTMENT OF PSYCHIATRY 1153 Centre Street Boston, MA 02130 Who We Are Brigham and Women s Faulkner Hospital (BWFH) Department of Psychiatry is the largest clinical psychiatry site in the Brigham / Faulkner
South West London and St George s Mental Health NHS Trust A National Service for Obsessive-Compulsive Disorder and Body Dysmorphic Disorder Springfield University Hospital A Referrer s Guide 1 Who we are
Depression in adults with a chronic physical health problem Treatment and management Issued: October 2009 NICE clinical guideline 91 guidance.nice.org.uk/cg91 NICE has accredited the process used by the
Mechanisms of change in cognitive therapy and interpersonal therapy for depression: preliminary results from an ongoing trial Marcus Huibers and Lotte Lemmens Department of Clinical Psychological Science,
The pharmacological management of aggression in the nursing home requires careful assessment and methodical treatment to assure maximum safety for patients, nursing home residents and staff. Aggressive
Treating Major Depressive Disorder A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition, originally published in October 2010.
1 Chapter 38. Major Depressive Disorders, Self-Assessment Questions 1. Which of the following SSRIs requires up to a 5-week washout period because of the long half-life of its potent active metabolite?
Addiction Psychiatry Program Site Specific Goals and Objectives Addiction Psychiatry (ADTU) Goal: By the end of the rotation fellow will acquire the knowledge, skills and attitudes required to recognize
Medical Necessity and Level of Care Determination Criteria The current version of this document is the online version. It can be found at priorityhealth.com/provider/manual/auths/bh/mednecessity/. Priority
TREATING PANIC DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Panic Disorder, originally published in May 1998. A guideline watch, summarizing significant
Issue date: October 2009 Depression Treatment and management of depression in adults, including adults with a chronic physical health problem This is an update of NICE clinical guideline 23 Developed by
COMPLEXITIES OF BIPOLAR DISORDER Interview with Charles B. Nemeroff, MD, PhD Dr Nemeroff is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
Database of randomized trials of psychotherapy for adult depression In this document you find information about the database of 352 randomized controlled trials on psychotherapy for adult depression. This
Adapted from Thase, M., Demitrack, M., Evaluating Clinical Significance of Treatment Outcomes in Studies of Resistant Major Depression Biological Psychiatry, April 1, 2008, Vol. 63:7s, Page 138s Evaluating
Pacific University CommonKnowledge Faculty Scholarship (PHRM) School of Pharmacy 2010 Psychotherapeutic Medication: Treatment Resistant Depression David Fuentes Pacific University Follow this and additional
Amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised prescribing advice for venlafaxine*. This amendment brings the guideline into line with the new advice but does
E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population
Practical Psychopharmacology of Autism Spectrum Disorders Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),
2014-2015 ISST CERTIFICATION REQUIREMENTS AS AN INDIVIDUAL SCHEMA THERAPIST Qualifications to apply for Certification for those completing training after December 31, 2013: To qualify for certification
PSYCHIATRIC MEDICATIONS IN PREGNANCY AND LACTATION Lauren O Brien, MD PGY3 11/5/14 OBJECTIVES Identify common psychiatric illnesses Discuss the categorization of medication in pregnancy and lactation Review
TREATMENT GUIDELINES Psychopharmacotherapy for Children and Adolescents Guideline 7 Psychopharmacotherapy for Children and Adolescents Description There are few controlled trials to guide practitioners
Behavioural and Cognitive Psychotherapy, 2006, 34, 95 101 Printed in the United Kingdom doi:10.1017/s1352465805002511 Treatment of Mixed Anxiety-Depression Disorder: Long-Term Outcome Enrique Echeburúa,
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also
MUS and psychiatry in primary care Henriëtte van der Horst VUmc Head of Department of General Practice and Elderly Care Medicine Double Dutch: two topics Major changes in the mental health care organisation
Vortioxetine for treating major depressive e episodes Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta367 NICE 2015. All rights reserved. Contents 1 Guidance... 3 2 The
Best Evidence Summaries of Topics in Mental Healthcare BEST in MH clinical question-answering service Question In adults with a diagnosis of psychotic / delusional depression how effective is electroconvulsive
PTSD Evidence ased Practice Recommendations Jason's ox est Practice Group Dr. Sam Moreno, Michelle Schnack Compilation & consolidation of the research and recommendations located in: The VA/DoD Clinical
Cognitive and Mood Disorders in Parkinson s Disease Video Transcript This is the first of two videos describing non-motor symptoms of Parkinson s disease. In this video we discuss cognitive and mood disorders
Inpatient Programs General Hospital Information General Information The Melbourne Clinic is a purpose built psychiatric hospital established in 1975, intially privately owned by a group of psychiatrists
Formulary and Prescrib bing Guidelin nes SECTION 4: TREATMENT OF ANXIETY 4.1 Introduction This guidance should considered as part of a stepped care approach in the management of generalised anxiety disorder
Issue date: December 2004 Quick reference guide Depression: management of depression in primary and secondary care Clinical Guideline 23 Developed by the National Collaborating Centre for Mental Health
THE UNIVERSITY OF TEXAS AT AUSTIN SCHOOL OF SOCIAL WORK Course Number: SW 393R1 Instructor s name: Cynthia Franklin, Ph.D e-mail: Unique Number: 61040 Office Number: SSW 3.106 email@example.com
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is bitemporal ECT more effective than
Depression is a biological brain disorder that is common in nursing home residents and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including
OUTPATIENT DAY SERVICES Intensive Outpatient Programs (IOP) Intensive Outpatient Programs (IOP) provide time limited, multidisciplinary, multimodal structured treatment in an outpatient setting. Such programs
Draft Document for HEDIS 2016 Public Comment Obsolete After March 18, 2015 1 Proposed New Measures for HEDIS 1 Learning Collaborative: Depression Care Measures Set NCQA s theme for 2015 our 25th anniversary
136 198 2004 2003 14 12 %13.2 17 %7.1 %9.6 3 32 9 Depression in childhood and adolescence is among the commonest and more disabling disorders. It has been reported that childhood depression ranges from
Key Information on the use of Antidepressants in Scotland KEY INFORMATION ON THE USE OF ANTIDEPRESSANTS IN SCOTLAND The prescription of antidepressant medication in the treatment of depression attracts
75 CURRENT AND EMERGING THERAPEUTICS FOR DEPRESSION A. JOHN RUSH NEAL D. RYAN This chapter discusses critical conceptual and practical issues confronting clinicians who must distill the massive neuroscientific,
IMPACT: An Evidence-based Approach to Integrated Depression Care Beth Israel Medical Center New York, NY 8:00 Registration & Continental Breakfast 8:30 Welcome & Introductions Day One: June 8, 2011 8:45
Western Australian Psychotropic Drugs Committee Anxiety Disorders Drug Treatment Guidelines August 2008 www.watag.org.au Table of Contents Executive Summary... 4 Psychological or pharmacological treatment?...
THE OFFICE OF SUBSTANCE ABUSE SERVICES REQUIREMENTS FOR THE PROVISION OF RESIDENTIAL DETOXIFICATION SERVICES BY PROVIDERS FUNDED WITH DBHDS RESOURCES PURPOSE: The goal of this document is to describe the
Depression in adults The treatment and management of depression in adults Issued: October 2009 NICE clinical guideline 90 guidance.nice.org.uk/cg90 NHS Evidence has accredited the process used by the Centre
Patterns of Interpersonal Problems Associated with Binge Eating Disorder Kathleen L. Eldredge, 1 * Kenneth D. Locke, 2 and Leonard M. Horowitz 3 1 Department of Psychiatry and Behavioral Sciences, Stanford
CHRONIC PAIN AND RECOVERY CENTER Exceptional Care in an Exceptional Setting Silver Hill Hospital is an academic affiliate of Yale University School of Medicine, Department of Psychiatry. SILVER HILL HOSPITAL
Mental Health and Substance Abuse Services in Medicaid and SCHIP in Florida As of July 2003 2,441,266 people were covered under Florida's Medicaid and SCHIP programs. There were 2,113,820 enrolled in the
New Treatments For Bipolar Disorder Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine Abbott Laboratories AstraZeneca Bristol-Myers Squibb Corcept
Your consent to our cookies if you continue to use this website.